Evidence map›Paper›PMID 26586467›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2016

The prototoxin LYPD6B modulates heteromeric α3β4-containing nicotinic acetylcholine receptors, but not α7 homomers.

Vanessa Ochoa, Andrew A George, Rae Nishi, Paul Whiteaker

Abstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 33 citations in OpenAlex.

  1. Lypd6b depletion promotes CD8Nature communications · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. HumanOncotarget · 2023
    Article
  7. Article
  8. Orientational Preferences of GPI-Anchored Ly6/uPAR Proteins.International journal of molecular sciences · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Vanessa Ochoa*Neuroscience Graduate Program, Department of Neurological Sciences, University of Vermont, Burlington, Vermont, USA; and Division of Neurobiology, Barrow Neurological Institute, Phoenix, Arizona, USA.
Andrew A George*Neuroscience Graduate Program, Department of Neurological Sciences, University of Vermont, Burlington, Vermont, USA; and Division of Neurobiology, Barrow Neurological Institute, Phoenix, Arizona, USA.
Rae Nishi*Neuroscience Graduate Program, Department of Neurological Sciences, University of Vermont, Burlington, Vermont, USA; and Division of Neurobiology, Barrow Neurological Institute, Phoenix, Arizona, USA rnishi@mbl.edu.
Paul Whiteaker*Neuroscience Graduate Program, Department of Neurological Sciences, University of Vermont, Burlington, Vermont, USA; and Division of Neurobiology, Barrow Neurological Institute, Phoenix, Arizona, USA.
Barrow Neurological Institute · USUniversity of Vermont · US

Funding

Variants in CHRNA5/CHRNA3/CHRNB4 and nicotine dependenceR21DA027070 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI CHEN, XIANGNING · 2009 to 2010
$897k
Nicotinic acetylcholine receptors and neuroblastomaR21NS076969 · NINDS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI NISHI, RAE · 2011 to 2012
$419k
Construction and Expression of Concatemeric alpha6beta2* Nicotinic Acetycholine RR21DA026627 · NIDA · ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER · PI WHITEAKER, PAUL · 2009 to 2010
$407k
NIDA NIH HHS R21 DA026627NIDA NIH HHS R21 DA027070NINDS NIH HHS R21 NS076969
6 · The paper itself

Abstract

Prototoxins are a diverse family of membrane-tethered molecules expressed in the nervous system that modulate nicotinic cholinergic signaling, but their functions and specificity have yet to be completely explored. We tested the selectivity and efficacy of leukocyte antigen, PLAUR (plasminogen activator, urokinase receptor) domain-containing (LYPD)-6B on α3β4-, α3α5β4-, and α7-containing nicotinic acetylcholine receptors (nAChRs). To constrain stoichiometry, fusion proteins encoding concatemers of human α3, β4, and α5 (D and N variants) subunits were expressed in Xenopus laevis oocytes and tested with or without LYPD6B. We used the 2-electrode voltage-clamp method to quantify responses to acetylcholine (ACh): agonist sensitivity (EC50), maximal agonist-induced current (Imax), and time constant (τ) of desensitization. For β4-α3-α3-β4-α3 and β4-α3-β4-α3-α3, LYPD6B decreased EC50 from 631 to 79 μM, reduced Imax by at least 59%, and decreased τ. For β4-α3-α5D-β4-α3 and β4-α3-β4-α-α5D, LYPD6B decreased Imax by 63 and 32%, respectively. Thus, LYPD6B acted only on (α3)3(β4)2 and (α3)2(α5D)(β4)2 and did not affect the properties of (α3)2(β4)3, α7, or (α3)2(α5N)(β4)2 nAChRs. Therefore, LYPD6B acts as a mixed modulator that enhances the sensitivity of (α3)3(β4)2 nAChRs to ACh while reducing ACh-induced whole-cell currents. LYPD6B also negatively modulates α3β4 nAChRs that include the α5D common human variant, but not the N variant associated with nicotine dependence.

Indexed as

AcetylcholineAnimalsHumansNicotineOocytesProtein SubunitsReceptors, NicotinicReceptors, Urokinase Plasminogen ActivatorXenopus laevisAcetylcholineNicotinenicotinic receptor alpha3beta4Protein SubunitsReceptors, NicotinicReceptors, Urokinase Plasminogen ActivatorCHRNA5Ly6/uPARLYNX1LYNX2PSCA

Identifiers

PMID26586467
PMCPMC4750422
OpenAlexW2181213288

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.